Annabel Webb

Annabel Webb has over 30 years of work experience in the pharmaceutical industry. Currently, they are working as the Lead, Clinical Operations EMEA at Amylyx Pharmaceuticals since September 2022. Prior to this, they worked at Novartis Gene Therapies as a Senior Clinical Trial Operations Manager from September 2020 to April 2022, overseeing global and European pediatric phase II-III trials in spinal muscular atrophy. ANNABEL also managed CROs and vendors during this role.

Before Novartis Gene Therapies, Annabel Webb served as a Senior Manager, Clinical Trial Operations (EMEA) at AveXis, Inc. from April 2019 to September 2020. ANNABEL was responsible for clinical trial operations in Europe, the Middle East, and Africa.

Annabel Webb has also held positions at Synteract and Novartis, where they worked as a Project Director and Regional Manager, respectively. At Synteract, they managed global and European phase II-IV projects in various therapy areas and was involved in study document development, proposal development, and bid defense meetings. During their tenure at Novartis, they were responsible for managing a team of Clinical Research Associates, providing training and mentoring, and overseeing primary and secondary care studies.

Earlier in their career, Annabel Webb worked at PAREXEL as a Manager, Clinical Operations, where they managed the UK Clinical Operations department and had responsibilities for resourcing, coaching, and performance management. ANNABEL also held the position of Senior Clinical Research Associate at PAREXEL. Additionally, they gained experience as a Clinical Research Associate at Ethical Pharmaceuticals, managing and monitoring phase I-III clinical trials in multiple therapeutic areas.

Overall, Annabel Webb has a strong background in clinical trial operations, project management, and cross-functional leadership in the pharmaceutical industry.

Annabel Webb (Ballantine) holds a Bachelor's degree in Physiology, General from The University of Sheffield.